APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)
11. September 2023 07:00 ET
|
APRINOIA Therapeutics, Inc.
Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic PipelinesFunding Supports APRINOIA’s Goal to Bring a Central Nervous...
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
28. August 2023 11:00 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
23. August 2023 17:21 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...